Pressefach: Capsulution Pharma AG

Capsulution Nanoscience on the Upswing

Berlin-based Nanotechnology Company fulfils revenue expectations

(PresseBox) Berlin, 22.02.2007, Good times for nanotechnology companies. The Berlin-based Capsulution Nanoscience AG fulfilled its turnover expectations in 2006 with more than 1.3 million euro. In comparison to the year before, the developers of nanotechnological “active component packages” managed with this an increase of about 50 %. The personnel figures rose to a final 20 members of staff, more than half of which are highly-qualified scientists and laboratory staff in the field of research and development.

As well as carrying out numerous customer projects, Capsulution has undertaken vital steps to test its own technology in preclinical studies and adapt to the requirements of industrial customers, evident in its collaboration with the Charité, started at the end of 2006. Due to such preliminary developments, the EBIT margin with about TEUR -150 still turned out negatively. “With this operational result, our company is clearly faring better than many other start-up technology companies in the same field”, states Alexander Herrmann, CFO.

Herrmann is optimistic about the year to come: “Our aim is not only to increase the turnover to double figures but also to break even.” These high expectations are based not in the least on the positive developments of the past months. Since November, Capsulution has, with the additional granting of its basis patent for its LBL Technology yet another competitive edge on the competition.

Speaking for the good growth prognoses are further well-known partner and customer acquisitions with commissioned developments in innovative nanoproducts forged in the last year, such as the published developments with the Schering AG (today Bayer Schering Pharma AG) or the Eyesense AG.

About Capsulution Pharma AG

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulution has recently designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulution's LBL capsules.

Further press release of this company

• 22.02.2010 - Into the future with a stronger team
• 17.11.2008 - Capsulution and NanoDel merge their businesses
• 17.11.2008 - Capsulution und NanoDel schließen sich zu Capsulution Pharma...
• 21.07.2008 - MIDAS Pharma und Capsulution unterzeichnen Kooperationsvertrag
• 21.07.2008 - MIDAS Pharma and Capsulution sign Cooperation Contract
• 14.07.2008 - Advanced Materials Technology und Capsulution NanoScience AG...